BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31597837)

  • 1. [Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update].
    Miura M; Takahashi N
    Rinsho Ketsueki; 2019; 60(9):1140-1147. PubMed ID: 31597837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
    Miura M
    Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.
    Yokoyama Y; Nozawa E; Morita M; Ishikawa E; Mori T; Sakurai M; Kikuchi T; Matsuki E; Yamazaki R; Kataoka K; Jibiki A; Kawazoe H; Suzuki S; Nakamura T
    J Clin Lab Anal; 2022 Aug; 36(8):e24598. PubMed ID: 35819095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic myeloid leukemia].
    Usui N
    Nihon Rinsho; 2014 Jun; 72(6):1068-72. PubMed ID: 25016806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis.
    Mukai Y; Yoshida Y; Yoshida T; Kondo T; Inotsume N; Toda T
    Ther Drug Monit; 2021 Jun; 43(3):386-393. PubMed ID: 33065614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
    Deb S; Boknäs N; Sjöström C; Tharmakulanathan A; Lotfi K; Ramström S
    Cancer Med; 2020 Jan; 9(1):313-323. PubMed ID: 31714021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
    Thienelt CD; Green K; Bowles DW
    Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
    Yilmaz M; Jabbour E
    Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    García-Ferrer M; Wojnicz A; Mejía G; Koller D; Zubiaur P; Abad-Santos F
    Clin Ther; 2019 Dec; 41(12):2558-2570.e7. PubMed ID: 31812340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
    Moslehi JJ; Deininger M
    J Clin Oncol; 2015 Dec; 33(35):4210-8. PubMed ID: 26371140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.
    Gurion R; Raanani P; Vidal L; Leader A; Gafter-Gvili A
    Acta Oncol; 2016; 55(9-10):1077-1083. PubMed ID: 27560448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
    Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 19. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
    Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
    Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.